AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04162106 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Smoke management during laparoscopic cholecystectomy using the Airseal® iFS
Description: The Airseal® iFS will be used during the procedure to manage smoke generated as a result of the use of diathermy.
Study NCT01302002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Pre-Surgery
Description: 500 mg tablet, taken twice a day for 3 weeks
Study NCT04427293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib 12mg daily for 7 days prior to surgery
Study NCT04427293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg IV on day 1
Study NCT05018364 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Serum erythropoietin level
Description: Evaluate serum erythropoietin level in neonates exposed to hypoxia compared to control group
Study NCT02987582 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion-focused mindfulness group
Description: Intervention The group will run for 8-weeks. Each group session is 2 and a half hours. Half way through the intervention there will be a 5 hour retreat on the weekend. A typical group format includes 20-40 minutes of meditation, followed by 10 minutes of independent journaling. Then group members will have time to report on recollections from meditation and facilitators will provide feedback. There is a break and the second part of the group focuses on a didactic teaching topic. Topics change each week; groups will run between October 2016 and June 2018.
Study NCT01101607 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Distal Forearm Fracture Reduction
Description: Fracture reduction
Study NCT02539550 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02539550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06266047
Description: PF-06266047
Study NCT00255099 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TMC125
Description: 2 x 100 mg tablets b.i.d. / 96 weeks
Study NCT00255099 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 tablets b.i.d. / 96 weeks
Study NCT04345497 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diabetes-Specific Formula
Description: Diabetes-Specific Formula and Standard of Care
Study NCT04345497 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard Of Care
Description: Standard of Care
Study NCT03372603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2798745
Description: GSK2798745 tablets will be available as white to almost white, round, film-coated tablets (micronized active pharmaceutical ingredient \[API\]) to be taken with a glass of water (approximately 240 mL).
Study NCT02325037 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo multiple doses
Description: Multiple doses, daily for 14 days, oral suspension, matching placebo
Study NCT03372603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets will be available as white to almost white, round, film-coated tablets to be taken with a glass of water (approximately 240 mL).
Study NCT02747147 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TIVA blood collection device
Description: the device is attached to a peripheral IV catheter for use as a direct blood draw device into a vacuum tube or a syringe
Study NCT02867462 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard care
Description: standard care
Study NCT02867462 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: manipulator consultation radiotherapy added to standard care
Study NCT02639065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 1500 mg IV every 4 weeks (1 cycle) for a maximum 13 doses (12 months), or until unacceptable toxicities or disease recurrence.
Study NCT04523220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1213790 (Osocimab)
Description: Single loading dose as subcutaneous abdominal injection followed by monthly maintenance doses.
Study NCT04523220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous administration in the same manner as Osocimab.
Study NCT04523220 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous administration in the same manner as Osocimab.
Study NCT04638257 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lactobacilli rhamnosus GR-1 and Lactobacilli fermentum RC-14
Description: Daily oral Lactobacilli starting at =\<18 weeks of gestation in singleton pregnancy
Study NCT04638257 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily oral placebo starting at =\<18 weeks of gestation in singleton pregnancy
Study NCT02011971 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinpocetine
Description: Vinpocetine is a chemical obtained from the leaves of the Lesser Periwinkle. It has been shown to improve cerebral metabolism and memory in animals and humans. In addition, it has been shown to enhance long-term potentiation, which has been linked to memory mechanisms. Furthermore, vinpocetine has been shown to have anticonvulsant effects and is more potent than several commonly used antiepileptic drug
Study NCT02011971 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vinpocetine
Description: Vinpocetine is a chemical obtained from the leaves of the Lesser Periwinkle. It has been shown to improve cerebral metabolism and memory in animals and humans. In addition, it has been shown to enhance long-term potentiation, which has been linked to memory mechanisms. Furthermore, vinpocetine has been shown to have anticonvulsant effects and is more potent than several commonly used antiepileptic drug
Study NCT02605824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: n-acetylcystine
Description: NAC is a mucolytic drug.
Study NCT02605824 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% saline
Description: Normal saline is a placebo agent.
Study NCT01989897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saline with 1mg/ml Histamine base
Study NCT01989897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diluent, saline with HSA--phenol
Study NCT02007304 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eccentric exercise training
Description: 12 weeks of lower leg eccentric training
Study NCT02592252 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Participatory gender training
Description: 10 sessions of participatory gender training
Study NCT02592252 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Microfinance
Description: Microfinance loan
Study NCT04650711 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: p16 protein expression
Description: P16INK4A immunohistochemical staining is to be performed in residual cytology samples.
Study NCT00636558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVA21
Description: IV infusion, dose escalation of one or two infusions of escalating strength
Study NCT00873015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium nitrite
Description: 14 day continuous infusion of one of 3 escalating doses of sodium nitrite: 32 nmol/min/kg, 48 nmol/min/kg, or 64 nmol/min/kg
Study NCT00873015 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 14 day continuous infusion of a vehicle control infusion
Study NCT04345809 — intervention group
Intervention type: PROCEDURE
Intervention: MESH WHIT OMEGA-3
Description: Mesh placement with Omega-3 at the umbilical trocar level after laparoscopic cholecystectomy in patients with risk factors for SSI and eventration.
Study NCT04345809 — intervention group
Intervention type: PROCEDURE
Intervention: MESH WITHOUT OMEGA-3
Description: Mesh placement without Omega-3 at the umbilical trocar level after laparoscopic cholecystectomy in patients with risk factors for SSI and eventration.
Study NCT03128411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib
Description: All patients will receive bosutinib at a starting dose of 400 mg QD.
Study NCT02610725 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Hatha yoga
Description: Participants will be shown a 30 minute video of a yoga class that they will be invited to follow along with.
Study NCT02030041 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Vitamin D will be given to achieve normal serum levels
Study NCT02030041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Simvastatin in a dose of 40 mg will be provided to the study participants
Study NCT02030041 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: Simvastatin in a dose of 40 mg will be provided to the study participants
Study NCT02030041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be provided to the study participants
Study NCT02030041 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo will be provided to the study participants
Study NCT00384566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: anit hypertensive medication
Study NCT00384566 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol
Description: Anti hypertensive medication
Study NCT01425996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipotecan® (TLC388)
Description: * Cohort A1: TLC388 15 mg/m2 x 6 dose + 3DCRT~* Cohort A2: TLC388 30 mg/m2 x 6 dose + 3DCRT~* Cohort A3: TLC388 40 mg/m2 x 6 dose + 3DCRT~* Cohort A4: TLC388 50 mg/m2 x 6 dose + 3DCRT (dose-escalation)~* Cohort Ax: TLC388 MTD x 6 dose + 3DCRT
Study NCT00978198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1517
Description: oral
Study NCT02007304 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Eccentric exercise training
Description: 12 weeks of lower leg eccentric training
Study NCT00978198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral
Study NCT01084083 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Given IV
Study NCT01084083 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy (IMRT)
Description: Patients undergo low-dose OR standard dose IMRT based on their clinical response to induction therapy
Study NCT01084083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV, 90 mg/m\^2 on days 1, 8 and 15
Study NCT01084083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV, 75 mg/m\^2 on day 1
Study NCT02375074 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supported Employment
Description: Supported Employment (SE), focusing on competitive employment in real-life settings without long-lasting preceding training.
Study NCT02375074 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Traditional Vocational Rehabilitation
Description: Traditional Vocational Rehabilitation (TVR), offering training and preparation for the labor market in a sheltered environment
Study NCT03196830 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-T
Description: For eligible patients, CAR-T cells targeted to patients' tumor cell antigen will be infused after 48 hours later of chemotherapy
Study NCT02996513 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Retinol Isotope Dilution (RID)
Description: 13C-retinyl acetate will be administered to subjects in order to assess their body retinol pools
Study NCT03715530 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: PAMG-1 immunoassay
Description: The procedure includes the insertion of a PAMG-1 swab into the subject's vaginal vault without a speculum for one minute. Once the swab is obtained, the treating physician will place the swab in a solvent vial for one minute. A developing strip is then placed in a vial and allowed to develop for five minutes. The results are read from the developing strip.
Study NCT03715530 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PAMG-1 immunoassay
Description: The procedure includes the insertion of a PAMG-1 swab into the subject's vaginal vault without a speculum for one minute. Once the swab is obtained, the treating physician will place the swab in a solvent vial for one minute. A developing strip is then placed in a vial and allowed to develop for five minutes. The results are read from the developing strip.
Study NCT03347630 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MRI
Description: Thoraco-abominal MRI
Study NCT00529360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Dose escalation of clofarabine on Days -9, -8, -7, -6, -5: 1 - 30 mg/m2; 2 - 40 mg/m2; 2 - 46 mg/m2; 3 - 52 mg/m2
Study NCT00529360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Use dose of clofarabine established in Part A to further define event free, disease free and overall survival.
Study NCT03510273 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Liger Medical Thermocoagulator
Description: Thermocoagulation treatment by Liger Medical device (US FDA 510K clearance received)
Study NCT00956293 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Basiliximab
Description: On day 0, 2 hours prior to transplant and day 4 post-transplant, 20 mg x2 were given to all participants. Post randomization, 20mg at weeks 7 and 12 were given to the Everolimus group.
Study NCT00956293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basiliximab
Description: On day 0, 2 hours prior to transplant and day 4 post-transplant, 20 mg x2 were given to all participants. Post randomization, 20mg at weeks 7 and 12 were given to the Everolimus group.
Study NCT00956293 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enteric Coated Mycophenolic Acid (MPA)
Description: A loading dose regimen of 2880 mg/day during weeks 1 and 2 (pre-randomization) were given. During weeks 3 - 6 (pre-randomization), 2160 mg/day were given and during weeks 7 - 24, 1440 mg/day were given if tolerated. Dose reductions due to side effects were possible.
Study NCT00956293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enteric Coated Mycophenolic Acid (MPA)
Description: A loading dose regimen of 2880 mg/day during weeks 1 and 2 (pre-randomization) were given. During weeks 3 - 6 (pre-randomization), 2160 mg/day were given and during weeks 7 - 24, 1440 mg/day were given if tolerated. Dose reductions due to side effects were possible.
Study NCT00956293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: Upon randomization, 3 mg (od) on Day 1, and 3 mg (1.5 mg every 12 hours) on Day 2 was given. Afterwards, the dosage was based on blood trough level (5 - 10 ng/mL).
Study NCT00956293 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporin A (CsA)
Description: Dosage was based according to blood level
Study NCT00956293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA)
Description: Dosage was based according to blood level
Study NCT00956293 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids
Description: Dosage was administered according to local standards and administration was optional as per clinical need and the Investigators' discretion. Steroid withdrawal occurred after week 2 (pre-randomization).
Study NCT00956293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: Dosage was administered according to local standards and administration was optional as per clinical need and the Investigators' discretion. Steroid withdrawal occurred after week 2 (pre-randomization).
Study NCT00327912 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Biliopancreatic diversion with Duodenal switch
Study NCT00327912 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Roux-en-Y Gastric Bypass
Study NCT03807583 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aminoven 10%
Description: After randomization to the visit Day 60, two months after patients inclusion (Visit Day 0) and one month after clinical examination (Visit Day 30), patients will be assigned to a group:~* group A: RENORAL® product~* group B: AMINOVEN® 10% product~* group C: control group (without intradialytic supplementation)~Patients will consume the products and will be followed for 3 months, one visit per month (Day 90, Day 120, Day 150). Protocol visits are included in the patient's course of care.
Study NCT03807583 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: RENORAL
Description: After randomization to the visit Day 60, two months after patients inclusion (Visit Day 0) and one month after clinical examination (Visit Day 30), patients will be assigned to a group:~* group A: RENORAL® product~* group B: AMINOVEN® 10% product~* group C: control group (without intradialytic supplementation)~Patients will consume the products and will be followed for 3 months, one visit per month ( V3, V4, V5). Protocol visits are included in the patient's course of care.
Study NCT02343315 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS
Description: Six treatment sessions will be given over two weeks. Total duration of the treatment session may last from 40 - 60 minutes.~* Equipment- TENS (CEFAR Basic TENS Machine)~* Electrodes- Four channel electrode to cover the site of pain~* Site of electrode placement- will be decided by the physical therapist to best suit or cover the area of pain based on complaints of patient based on the body chart.~* Intensity- the intensity will be increased progressively until maximum tolerable intensity is reached. This stimulation may cause visible muscle contraction. This type of current is also referred to as Motor-level TENS, which is effective for chronic pain. The intensity will not be increased beyond 25 milli Amperes if no sensation is perceived by the patient.~* Frequency- 5 Hertz~* Duration- 30 minutes
Study NCT02343315 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMCE
Description: Six sessions of supervised Motor control exercises will be provided over the period of two weeks. Exercises will be provided in order to target the function of core muscles of the spine. Each participant in the SMCE group will be trained by a physical therapist to recruit the deep muscles of the spine and reduce the activity of superficial muscles.~Initially participants will be taught how to contract the transversus abdominis and multiﬁdus muscles in isolation from the more superﬁcial trunk muscles, but in conjunction with the pelvic ﬂoor muscles. Pressure biofeedback will be used in order to provide feedback about muscle recruitment to the participant. Exercises will be provided to the participants in the progressive manner. Later, movement of limbs will be incorporated with the contraction of the core muscles. Finally, these core muscle activation will be emphasized during the functional activities.
Study NCT02343315 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: UHEP
Description: All the participants will receive the following treatments:~1. Unsupervised home exercise program- which includes series of motor control exercises along with specific exercises including stretching exercises based on impairments.~2. Education in terms of body mechanics, ergonomics advises and educational leaflet in the form of Nepali version of Back book which includes, evidence based advises about back pain self-management, advice to remain active. Treating physical therapist will educate all the participants in the first intervention session.~3. Participants will not be asked to not take the over the counter analgesics including Acetaminophen or Non-inflammatory anti-inflammatory drugs (ibuprofen).
Study NCT02343315 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: UHEP
Description: All the participants will receive the following treatments:~1. Unsupervised home exercise program- which includes series of motor control exercises along with specific exercises including stretching exercises based on impairments.~2. Education in terms of body mechanics, ergonomics advises and educational leaflet in the form of Nepali version of Back book which includes, evidence based advises about back pain self-management, advice to remain active. Treating physical therapist will educate all the participants in the first intervention session.~3. Participants will not be asked to not take the over the counter analgesics including Acetaminophen or Non-inflammatory anti-inflammatory drugs (ibuprofen).
Study NCT02960425 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Delivra TM Livsport preworkout cream
Description: High versus low dose topical creatine
Study NCT02960425 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Topical placebo
Study NCT04549480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib capsule
Description: 100 mg dose of bosutinib pediatric capsule
Study NCT04549480 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bosutinib tablet
Description: 100 mg dose of bosutinib tablet
Study NCT01840033 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: group Piccnut
Description: Vessels echography will be systematically repeated at 3 months and 12 months for thrombosis research. Follow-up visit will be held at 1,3,6,9 and 12 months. At every step, major and minor complications will be noted by the investigators.